Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

アブストラクト
ジャーナル名	JAAD international
Pubmed追加日	2026/4/13
投稿者	Alomary, Simona A; Baker, Nicole J; Ogunleye, Temitayo; Taylor, Susan C
組織名	Rutgers New Jersey Medical School, Newark, New Jersey.;Department of Dermatology, Perelman School of Medicine at the University of;Pennsylvania, Philadelphia, Pennsylvania.;Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia,;Pennsylvania.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41969289/